Work

Zanzalintinib Plus Pembrolizumab Versus Pembrolizumab Alone In Patients with PD-L1 Positive Metastatic Head And Neck Squamous Cell Carcinoma (STELLAR-305): A Double-Blind, Randomized, Placebo-Controlled, Phase 2/3 Study

Year: 2024

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2024.01.092

Authors: N.F. Saba, K. Harrington, L. Licitra, J.P. Machiels, M. Huang, F. Xu, P. Patel, R.I. Haddad

Institutions: Winship Cancer Institute, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, National Institute for Health and Care Research, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Cliniques Universitaires Saint-Luc, Exelixis (United States), Dana-Farber Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392827103

FWCI: 0.307

Cites:

Cited by: 2

Related to: 10